Skip to content
Clinical Trials – home

Bekes Varmegyei Koezponti Korhaz

Verified siteinfo

Hungary Semmelweis Utca 1, 5700 Gyula, Hungary

  • 35 trials recruiting
  • Systemic lupus erythematosus · Psoriatic arthropathy · Sjogren's syndrome
  • Adults and children

About Specializations

Bekes Varmegyei Koezponti Korhaz in Gyula, Hungary specialises in clinical trials of conditions such as Systemic lupus erythematosus, Psoriatic arthropathy, Sjogren's syndrome, Non-small cell lung cancer, and other specialisations. This site conducts important research.

Main research areas of the site

Respiratory and Thoracic Oncology

At Bekes Varmegyei Koezponti Korhaz in Gyula, a major share of research focuses on respiratory tract diseases and neoplasms, especially non-small cell lung cancer and related advanced lung tumors. These studies are designed to test new treatment approaches, compare them with current standards, and improve survival outcomes for people with difficult-to-treat cancers.

  • Non-small cell lung cancer and advanced lung cancer
  • Stage IV, metastatic, and PD-L1–positive disease
  • Evaluating new cancer therapies and combinations against established care

The site’s pulmonary department supports a broad oncology portfolio, with research aimed at better disease control, longer progression-free survival, and improved overall outcomes.

Breast and Prostate Cancer Research

The clinical trial program includes extensive work in breast cancer and prostate cancer, covering both early and advanced disease. Studies are exploring new endocrine-based strategies, targeted treatments, and combination approaches to reduce recurrence and improve disease control in hormone-driven cancers.

  • ER-positive, HER2-negative breast cancer
  • Metastatic breast cancer and high-risk early-stage disease
  • Prostate cancer, including metastatic castration-resistant and high-risk localized disease

Research at the site includes efforts to prevent recurrence, delay progression, and identify more effective options for patients whose cancer has returned or spread.

Autoimmune and Inflammatory Diseases

A strong portion of the research landscape centers on immune system diseases and chronic inflammatory conditions such as systemic lupus erythematosus, psoriatic arthritis, rheumatoid arthritis, and Sjögren’s syndrome. These trials are mainly aimed at improving symptom control, reducing disease activity, and assessing the long-term safety of newer immune-modulating treatments.

  • Systemic lupus erythematosus and related systemic autoimmune disease
  • Psoriatic arthritis and rheumatoid arthritis
  • Sjögren’s syndrome and other immune-mediated disorders

This area reflects a broad interest in therapies that may help patients live with fewer flares, less inflammation, and better daily function.

Cardiovascular and Metabolic Medicine

The site also conducts research in cardiovascular diseases and nutritional and metabolic diseases, including heart failure, acute myocardial infarction, hyperlipidaemia, and type 2 diabetes. These studies are focused on lowering cardiovascular risk, improving heart function, and testing whether newer therapies can better support long-term prevention and treatment.

  • Heart failure and inflammation-related cardiac disease
  • Acute myocardial infarction and prevention of recurrent events
  • Hyperlipidaemia and type 2 diabetes

Research in this field aims to reduce serious complications such as heart attack, stroke, and worsening heart failure while improving everyday disease management.

Infectious, Liver, and Surgical Care

Clinical trials at the hospital cover bacterial infections, virus diseases, and selected digestive system diseases, including chronic hepatitis B and primary biliary cholangitis. There is also work on preventing surgical infections and supporting safer care around urgent procedures.

  • Chronic hepatitis B and liver-related disease
  • Post-surgical infection prevention
  • Bacterial pneumonia and other serious infections

These studies are intended to improve infection control, support recovery after surgery, and explore better options for chronic liver conditions with ongoing symptoms.

Additional Chronic Disease and Symptom-Focused Research

Beyond the main specialty areas, Bekes Varmegyei Koezponti Korhaz participates in trials across a wide range of chronic conditions, including chronic obstructive pulmonary disease, chronic kidney disease, pruritus, and selected mental disorders in children and adolescents. The aim is often to improve symptom relief, strengthen disease control, or assess whether new therapies can offer better everyday outcomes.

  • COPD and other chronic respiratory conditions
  • Chronic kidney disease and multisystem inflammatory disease
  • Pruritus and symptom-driven quality-of-life research

This mix of studies shows a broad clinical research profile that extends beyond one specialty, with attention to both complex diseases and patient-reported symptoms.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location
Semmelweis Utca 15700 GyulaHungary
Recruiting now
35 trials
Conditions studied
55
Partner status
Verified site

More sites in GyulaHungary

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Condition
Type of trial
Recruitment status
Quick filters

97 clinical trials

Randomized Phase III trial of elecoglipron plus dapagliflozin on kidney outcomes and mortality in adults with chronic kidney disease

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:AZD5004
  • Sponsor:AstraZeneca AB

Zenagamtide Compared with Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

Study of sotorasib, panitumumab and a drug combination for patients with metastatic colorectal cancer with KRAS p.G12C mutation.

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years
  • Substances:Bevacizumab
  • Sponsor:Amgen Inc.

A Study of Ivonescimab Combined with Fluorouracil, Folinic Acid, and Oxaliplatin Compared to Bevacizumab for Patients with Metastatic Colorectal Cancer

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Summit Therapeutics Inc.

Cardiac failure

Recruiting

Study on BI 690517 and Empagliflozin for Patients with Heart Failure and Preserved Ejection Fraction

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:BI 690517
  • Sponsor:Boehringer Ingelheim International GmbH

Study on Selatogrel for Preventing Heart Attack in Patients with Recent Heart Attack History

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Selatogrel
  • Sponsor:Viatris Innovation GmbH

Study on Long-Term Safety of Ianalumab for Patients with Systemic Lupus Erythematosus

Registered drug
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Emtricitabine
  • Sponsor:Novartis Pharma AG

Study on the Effectiveness and Safety of Deucravacitinib for Adults with Active Sjogren's Syndrome

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Deucravacitinib
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Favezelimab
  • Sponsor:Merck Sharp & Dohme LLC

Zenagamtide versus semaglutide: a study of blood sugar and weight reduction in adults with type 2 diabetes inadequately controlled on metformin and/or SGLT2 inhibitor

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Novo Nordisk A/S

A study of the safety and efficacy of AC01 in patients with heart failure with reduced ejection fraction

Investigational
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Sponsor:AnaCardio AB

Gastric cancer+1

Recruiting

Study of AZD0901 (sonesitatug vedotin) with capecitabine ± rilvegostomig in adults with advanced stomach or esophageal cancer (Claudin‑18.2‑positive, HER2‑negative)

Registered drugNo placebo
Countries:HungaryHungary
  • Participants:18–64 years · 65+ years
  • Substances:AZD0901
  • Sponsor:AstraZeneca AB
Is this your site?

Join our network of research sites

Move up to Verified & featured: your own description, photos and phone number on this page, and top placement on every trial you run.

See the offer for sites
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.